Literature DB >> 1899434

Late potentials on signal-averaged electrocardiograms and patency of the infarct-related artery in survivors of acute myocardial infarction.

P J Vatterott1, S C Hammill, K R Bailey, C M Wiltgen, B J Gersh.   

Abstract

This study evaluated the relation between patency of the infarct-related artery and the presence of late potentials on the signal-averaged electrocardiogram (ECG) in 124 consecutive patients (98 men, 26 women; mean age 59 years) with acute myocardial infarction receiving thrombolytic therapy, acute percutaneous transluminal coronary angioplasty or standard care. All patients were studied by coronary angiography, measurement of ejection fraction and signal-averaged ECG. The infarct-related artery was closed in 51 patients and open in 73. Among patients with no prior myocardial infarction undergoing early attempted reperfusion therapy, a patent artery was associated with a decreased incidence of late potentials (20% versus 71%; no significant difference in ejection fraction). In the 48 patients receiving thrombolytic agents within 4 h of symptom onset, the incidence of late potentials was 24% and 83% among patients with an open or closed artery, respectively (p less than 0.04). The most powerful predictors of late potentials were the presence of a closed infarct-related artery, followed by prior infarction and patient age. Among patients receiving thrombolytic agents within 4 h of symptom onset, the only variable that was predictive of the presence of late potentials was a closed infarct-related artery. These data imply that reperfusion of an infarct-related artery has a beneficial effect on the electrophysiologic substrate for serious ventricular arrhythmias that is independent of change in left ventricular ejection fraction as an index of infarct size. These findings might explain, in part, the low late mortality rate in survivors of myocardial infarction with documented reperfusion of the infarct-related artery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899434     DOI: 10.1016/s0735-1097(10)80095-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  The Open Artery: Electrophysiologic Considerations.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction.

Authors:  K K Ray
Journal:  Heart       Date:  1996-07       Impact factor: 5.994

Review 3.  Aborted sudden cardiac death: a clinical perspective.

Authors:  P Mazeika
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

4.  Effects of Late Coronary Artery Reperfusion on Left Ventricular Remodeling Persist for 10 Weeks After Experimental Rat Myocardial Infarction and Are Associated with Improved Survival.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

5.  Routine Coronary Arteriography Following Thrombolytic Therapy for Acute Myocardial Infarction: An Unsettled Controversy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

6.  Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction.

Authors:  H V Huikuri; M J Koistinen; K E Airaksinen; M J Ikäheimo
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

7.  [Impact of a percutaneous transluminal coronary angioplasty on the prevalence of ventricular late potentials among patients with survived myocardial infarction].

Authors:  M Hennersdorf; C Perings; F C Schoebel; E G Vester; B E Strauer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1997-09

8.  Ventricular late potential in cardiac syndrome X compared to coronary artery disease.

Authors:  Mohamed Faisal Lutfi
Journal:  BMC Cardiovasc Disord       Date:  2017-01-19       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.